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Effect of Statin Therapy Duration on Bone Turnover 
Markers in Dyslipidemic Patients
Abstract
Background and Purpose: Statins are cholesterol-lowering drugs de-
creasing bone resorption by inhibition of the farnesyl diphosphate synthase step 
in the mevalonic acid pathway and therefore are believed to have beneficial 
effects on bone status. The objective was to examine the relationship between 
statin therapy duration and bone turnover markers in dyslipidemic patients. 
Patients and Methods: Two hundred and eighty subjects were divided 
into five groups depending on duration of statin therapy: (controls 0 yrs); (0.1-
1.5 yrs); (2-5 yrs); (6-10 yrs); (11-30 yrs). ELISA method was applied on fast-
ing serums using bone formation markers: Osteoprotegerin (pmol/l) and Os-
teocalcin (ng/ml) and bone resorption markers: sRANKL (pmol/l) and 
CrossLaps (ng/ml). In statistical analysis, multiple regressions were used.
Results: A common influence of studied predictor variables was statisti-
cally significant for sRANKL, Serum CrossLaps and osteocalcin (P<0.001), 
while statistical significance was not found for osteoprotegerin. The largest 
shares of contributions were recorded in Model 2 for the statin group (40%) 
and BMI (36%) and in Model 1 for statin group (35%) and total cholesterol 
(28%). 
Conclusions: Statins showed favorable influence on osteocalcin and 
sRANKL, indicating improved bone metabolism in patients with longer dura-
tion of statin therapy. 
 
INTRODUCTION
Dyslipidemia and osteoporosis are two clinically important medical issues with high prevalence in modern society. Nowadays, choles-
terol is associated with atherosclerosis and to all its consequences that 
every year affect a large number of victims around the world. Osteopo-
rosis is also a very common disease of modern times whose prevalence 
increases due to lifestyle and aging of population. In the course of cho-
lesterol synthesis, statins inhibit 3-hydroxy-3-methyl-glutaryl-CoA re-
ductase (HMG-CoA) of the mevalonate pathway, which significantly 
reduces the cardiovascular risk. It was found, however, that statins have 
other positive - pleiotropic effects. Thus, statins lower platelet aggrega-
tion, promote angiogenesis, reduce the production of beta amyloid pep-
tide which is associated with Alzheimer’s disease, suppress the activation 
of T cells (1, 2, 3). A positive effect on bone was also reported. Increased 
formation of bone tissue seems to depend on inhibition of the synthesis 
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of isoprenoid mediators of the mevalonate pathway which 
are important for posttranslational modification of cer-
tain proteins, such as Ras and Rho proteins (4). In 1999, 
Mundy reported in vivo impact of statins that increased 
bone mass of mice’s skulls (5). It was recently discovered 
that statins stimulate the expression of anabolic factors 
such as bone morphogenetic protein 2 (BMP-2) and vas-
cular endothelial growth factor (VEGF) (6). It is believed 
that statins activate the expression of BMP-2 in osteo-
blasts, as confirmed by deactivating expression of BMP-2 
after administration of mevalonate metabolites of HMG-
CoA reductase. The latter effect of the BMP-2 was found 
only with lipophilic statins (5). Some statins have also 
been described to regulate the function of osteoblasts by 
expressing bone sialoprotein (BSP), osteocalcin, and type 
I collagen (7). Statins enhance the differentiation of os-
teoblasts from stromal cells (8). The migration of osteo-
blasts plays an important role in the healing of fractures 
as well as during bone modeling and remodeling. It is 
stimulated by many growth factors, including platelet 
derived growth factor (PDGF).
 By reducing isoprenilation of the signaling molecules 
in mevalonate pathway (Rac-Akt), statins stimulate 
PDGF and thereby the healing of the bone (9). Clinical 
studies confirmed the positive effect of statins on bone 
mass density and bone remodeling (8, 9, 10). In a clinical 
study conducted by Montagnani et al. bone mineral den-
sity, as the gold standard for diagnosis of osteoporosis, and 
the concentration of bone remodeling markers were as-
sessed in patients using statins. Statins exhibit the best 
effect on bone remodeling after 4 to 12 weeks of treatment 
when a slight reduction in bone resorption markers was 
described (10). However, some other studies, such as the 
LIPID (Long Term Intervention in Ischemic Disease) and 
Simvastatin Survival Study, did not show such changes in 
bone remodeling (11). Some statins inhibit differentiation 
of the bone marrow mesenchymal cells in fatty cells and 
thus direct pluripotent cells to differentiate into osteo-
blasts (12, 13). Statins also suppress the expression of 
adipocyte-specific genes PPR-gamma-2 and adipocyte 
specific protein P2 and their maturation (13). The latter 
fact is important since the loss of bone mass was related 
to their increased accumulation in the bone, and also to 
an increased percentage of fat in the body (14, 15, 16). 
Positive effect of statins has not been confirmed in the 
prevention or treatment of osteoporosis. Researchers sus-
pect that the cause can be found in the following: the 
application of too low doses of statins, differences in the 
chemical structure of statins, and  or their metabolism in 
the liver. Thus, some researchers have tried to replace oral 
preparations with transdermal or topical preparations 
(17). Local application of gelatin sponges rich in statin 
helped the healing of mandibular defect in rats (18). As 
documented in the recent scientific literature, the key fac-
tors in the regulation of bone turnover, i.e. the receptor 
activator of nuclear factor kappa B ligand (RANKL) and 
its receptor RANK, are essential for the development, 
activation and apoptosis of osteoclasts (19).  Osteoprote-
gerin (OPG) or RANKL decoy receptor is a natural an-
tagonist of RANKL and it is produced by osteoblasts and 
endothelial cells. Recent studies suggest that statins could 
inhibit osteoclast activity indirectly by activating osteo-
blasts that produce osteoprotegerin, (20, 21). So far no 
study was conducted to examine the relationship between 
statins and RANK/RANKL/OPG system. The aim of 
this study was to correlate the duration of statin treatment 
with bone turnover markers in patients with dyslipidemia. 
PATIENTS AND METHODS
Patients
This study included women with dyslipidemia who 
were treated with statins (N  = 200). The control group 
consists of women (N = 80) who first presented for spe-
cialist examination because of suspected dyslipidemia. 
Considering the period of treatment with statins, respon-
dents were divided into four subgroups: Subgroup 1 con-
sists of control; subgroup 2 consists of patients who were 
treated with statins between 0.1 and 1.5 years; subgroup 
3 consists of patients who were treated with statins be-
tween 2 and 5 years; subgroup 4 consists of patients who 
were treated with statins between 6 and 10 years, and 
subgroup 5 consists of patients who were treated with 
statins between 11 and 30 years. Along with antilipemic, 
some of the the subjects received antiresorptive therapy 
for osteoporosis. Therefore, respondents were labeled with 
0 - not receiving treatment for osteoporosis/dyslipidemia 
and 1 - receiving therapy for osteoporosis/dyslipidemia. 
Methods
Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA was performed according to manufacturer’s 
protocol. Concentrations of the following bone turnover 
markers: C-terminal telopeptide of type I collagen (Serum 
CrossLaps); osteocalcin; soluble receptor activator of NF-
kappaB (sRANKL); osteoprotegerin (OPG) as well as 
parameters of lipid status (total cholesterol, high density 
lipoproteins-HDL, low-density lipoproteins-LDL and 
triglycerides) were determined in the sera collected from 
fasting subjects. Blood samples (8 ml) were centrifuged 
to obtain the sera (4 ml). Following manufacturer’s in-
structions, the values of the bone turnover markers were 
expressed in appropriate units of measure: RANKL 
(pmol/l), OPG (pmol/l), osteocalcin (ng/ml) and serum 
CrossLaps (ng/mL), vitamin D (nmol/l) (Biomedica 
Gruppe, Vienna, Austria).
Anthropometry 
Body weight was determined using portable electronic 
scales (Seca, Hamburg, Germany), with an accuracy of ± 
0.1 kg. Body height was measured using the moving sta-
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Descriptive characteristics of respondents (N=280).
Anthropometry and age Mean± SD Minimum Maksimum
Age (years) 65.82±6,4 50 81
Body weight (kg) 74.78±14,17 50 118
Body height (cm) 162.92±8,14 147 186
Body mass index, BMI (kg/m2) 27.59±4.18 18,5 40
Waist circumference (cm) 96.01±10.80 68 118
Hip circumference (cm) 103.43±9.36 81 130
Waist to hip ratio, WHR 0.9 0.7 1.1
Hemodynamic and lipid parameters
Systolic blood pressure (mmHg) 132.75±19.23 90 185
Diastolic blood pressure (mmHg) 83.61±11.32 50 105
Pulse rate (/min) 73,86±11,86 52 122
Total triglycerides (mmol/l) 1.37±0.5 0,5 2.7
Cholesterol (mmol/l) 5.60±1.32 2.6 9.2
LDL (mmol/l) 3.53±1.1 1.5 5.8
HDL (mmol/l) 1.52 0.8 3
Bone remodeling parameters
OPG (pmol/l) 3.23±1.33 0.43 7.26
sRANKL (pmol/l) 3.64±3.75 -0.35 19.12
Serum CrossLaps (ng/ml) 22.22±14.54 3.07 60.32
Osteokalcin (ng/ml) 14.26±10.77 4 45
LDL-low density lipoproteins; HD- high density lipoproteins; OPG-osteoprotegerin; sRANKL-soluble receptor activator of NFkappaB ligand; Serum 
CrossLaps- serum C-terminal telopeptide of type I collagen
diometer (Seca, Hamburg, Germany) with an accuracy of 
± 0.5 cm. Body mass index, BMI (kg/m2) was calculated 
from the known values of the body height and body 
weight. Waist to hip ratio (WHR, cm) was measured from 
the known values of the waist and hip circumference.
Statistical analysis
Statistical analysis was performed using the software 
Statistica 8.1 (StatSoft). Descriptive statistics was used to 
display all the examined variables. Kolmogorov-Smirnov 
test was used to determine normality of distribution. Re-
sults were normally distributed and multiple regression 
analysis was performed. The results were considered sta-
tistically significant at P <0.05.
Medical ethics
Medical data were collected in accordance with ethical 
and bioethical principles. Privacy (medical secret) and 
confidentiality were ensured for respondents of the survey. 
The study had been preceded by an informative meeting 
with the principal investigator and other co-workers who 
participated in the study. The subjects were personally 
acquainted with the importance, objectives and plan of 
research and voluntarily signed the informed consent to 
participate in the study.
RESULTS
Kolmogorov-Smirnov test showed normal distribution 
of respondents. Their age ranged from 50 to 81 years. The 
average age of respondents was 66 years. Most respon-
dents ranged between 60 and 70 years.
Tables 2 – 4 show the results of multiple regression 
analysis with  shares of  contribution of independent pre-
dictors to criterion variables, i.e. bone turnover markers 
(Osteocalcin, Serum CrossLaps, sRANKL and Osteopro-
tegerin). Prediction variables in Model 1 are  age (years), 
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The share of contribution of predictor variables for sRANKL.
Model R R2 F P
1  (a) 0.70 0.50 3.17 0.000
2  (b) 0.71 0.50 3.74 0.000
Model ß SE? r P Share of contribution (%)
1 (a) Age (years) 0.33 0.11 0.37 0.005 12
 Statin group (1-5) -0.78 0.22 -0.45 0.001 35
 WHR                                   0.54 0.22 0.31 0.021 17
 Total cholesterol (mmol/l) -0.93 0.41 -0.30 0.030 28
 LDL (mmol/ml) 0.82 0.37 0.29 0.032 24
2 (b) Age (years) 0.34 0.11 0.38 0.004 13
 Statin group (1-5) -0.81 0.22 -0.55 0.000 45
 WHR 0.55 0.22 0.32 0.016 18
 Total cholesterol (mmol/l) -0.94 0.41 -0.30 0.023 28
 LDL (mmol/l) 0.86 0.37 0.16 0.022 14
sRANKL (soluble receptor activator of NFkappaB ligand); b - regression coefficient; SEb- standard error of b coefficient; r-correlation coefficient; p <0.05
TaBlE 3
The share of contribution of predictor variables for Serum CrossLaps.
Model R R2 F P
1   (a) 0.55 0.31 3.17 0.03
2   (b) 0.60 0.36 3.74 0.04
Model ß SE? r P Share of contribution (%)
1 (a) Body mass index (kg/m2) -1,1 0,50 -0,30 0,031 33
2 (b) Body mass index (kg/m2) -1,2 0,50 -0,32 0,016 38
 Therapy for osteoporosis (yes/no) -0,3 0,14 -0,55 0,043 17
Serum CrossLaps (C-terminal telopeptide of type I collagen); b - regression coefficient; SEb- standard error of b coefficient; r-correlation coefficient; 
p <0.05
statin group (1-5), statin therapy (yes/no), body height 
(cm), body weight (kg), body mass index (kg/m2), waist 
circumference (cm), hip circumference (cm), waist to hip 
ratio (WHR), systolic blood pressure (mmHg), diastolic 
blood pressure (mmHg), total cholesterol (mmol/l), high 
density lipoproteins (HDL, mmol/L), low-density lipo-
proteins (LDL, mmol/l), triglycerides (mmol/ l), pulse rate 
(/min). In Model 2, prediction variables are the same as 
in Model 1, with inclusion of the variable therapy for os-
teoporosis (yes/no). If b is negative,  relationship is in-
versely proportional, while positive b indicates propor-
tional relationship. Osteoprotegerin was not significantly 
predicted by Model 1 or 2 and therefore is not shown.
DISCUSSION
In this investigation, it was determined that average 
waist circumference in subjects was 96 cm and the average 
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The share of contribution of predictor variables for Osteocalcin.
Model R R2 F P
1   (a) 0.96 0.92 41.03 0.000
2   (b) 0.96 0.93 40.39 0.000
Model ß SE? r P Share of contribution (%)
1 (a) Statin groups (1-5) 1.24 0.08 0.89 0.000 10
 Statin therapy (yes/no) -0.32 0.09 -0.45 0.001 14
 Systolic blood pressure (mmHg)                0.15 0.07 0.30 0.025 5
 Diastolic blood pressure (mmHg) -0.19 0.06 -0.30 0.005 6
2 (b) Statin groups (1-5) 1.23 0.08 0.90 0.000 10
 Statin therapy (yes/no) -0.32 1.85 -0.57 0.000 18
 Systolic blood pressure (mmHg) 0.15 0.06 0.31 0.021 5
 Diastolic blood pressure (mmHg) -0.16 0.07 -0.32 0.018 5
b - regression coefficient; SEb- standard error of b coefficient; r-correlation coefficient; p <0.05
of the waist to hip ratio was 0.9, which placed our respon-
dents into the risk group for the development of meta-
bolic syndrome. An average BMI in the subjects was 
around 28 kg/m2, which is bordering on severe obesity 
(BMI > 30 kg/m2). The association between body weight 
or BMI and bone mineral density at the spine or hip has 
already been established (22). When it is not possible to 
make bone densitometry, BMI is an important diagnostic 
criterion in the diagnosis of osteoporosis. Protective effect 
of obesity on development of osteoporosis in women is 
explained by the specific role of adipose tissue as a source 
of estrogen (22).
 BMI is a good indicator of bone metabolism, as con-
firmed by our result of inversely proportional relationship 
between Serum CrossLaps and BMI (Table 3). Thus, 
higher values of BMI are associated with lower serum 
Serum CrossLaps, suggesting less resorption of bone.
Multiple regression analyses revealed the largest shares 
of contributions recorded in Model 2 for the statin group 
(40%) and BMI (36%) and in Model 1 for statin group 
(35%) and total cholesterol (28%). 
Dyslipidemia and bone remodeling 
markers
Hyperlipidemia represents an increase in cholesterol 
and/or triglycerides in the blood, with a low value of high 
density lipoprotein (HDL), which leads to atherosclerosis. 
This disorder of metabolism of lipids is called dyslipid-
emia and is predicted to grow. Dyslipidemia is one of the 
most important risk factors for cardiovascular diseases 
which are the most common cause of death (23, 24,25). 
When the scientific literature notifies about the relation-
ship between dyslipidemia and bone metabolism, two 
links are emphasized: dyslipidemia is the basis for vascu-
lar calcifications as a result of advanced atherosclerosis of 
the blood vessels; oxidized low-density lipoproteins (LDL) 
inhibit differentiation of pre-osteoblasts into osteoblasts 
(23, 24). The literature has described a positive correlation 
between the bone mineral density and the concentration 
of triglycerides, and a negative correlation between the 
bone mineral density and the concentration of high den-
sity lipoproteins (HDL) in postmenopausal women (23, 
24, 25, 26).
The results of this study showed that a common influ-
ence of studied predictor variables was statistically sig-
nificant for sRANKL, Serum CrossLaps and osteocalcin 
(P<0.001), while statistical significance was not found for 
osteoprotegerin. The analysis of the influence of individ-
ual variables revealed a statistically significant and in-
versely proportional relationship between total choles-
terol and sRANKL (Table 2). Furthermore, it was found 
that total cholesterol has equal share of contributions 
(28%) for sRANKL in statin-treated patients, as well as 
in patients who, along with statins, took drugs for osteo-
porosis. Not only do our results indirectly confirm the 
above mentioned research of positive correlation between 
blood lipids and bone status but generally it can be said 
that a rise in cholesterol concentration coincides with re-
duced values  of sRANKL, suggesting a role of choles-
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terol in bone remodeling. This could have an inhibitory 
effect on the function of osteoclasts, resulting in reduced 
bone degradation. Actually, sRANKL is a ligand that 
binds to the RANK receptor on osteoclasts, which acti-
vates osteoclast-mediated resorption of bone tissue (20, 
21).
By increasing the concentration of triglycerides, the 
level of high density lipoproteins (HDL) lowers, and small 
dense particles called low-density lipoproteins (LDL) ap-
pear in circulation. LDL particles are atherogenic and 
considered to be the main risk factor for cardiovascular 
diseases and the leading cause of mortality in patients 
with diabetes mellitus (29). Mean LDL levels in our par-
ticipants were greater than 3.4 mmol/l and as such are 
considered critical values with the risk associated to in-
creased values (> 4.1 mmol/l). 
We found statistically significant and exactly propor-
tional relationship between LDL cholesterol and 
sRANKL, with a 24% share of contribution in patients 
taking lipid lowering drugs, and with 14% decrease in 
patients who took antiresorptive therapy along with anti-
lipemic therapy. LDL particles are elevated in obese peo-
ple, but their links with sRANKL and other inflamma-
tory cytokines are increasingly discussed in medical 
literature, with special reference to the metabolic syn-
drome (27, 28).
Inflammatory cytokines are physiologically secreted 
by fatty tissue. This refers to cytokines that have endo-
crine, autocrine and paracrine effect, such as leptin, adi-
ponectin, TNF-?, resistin, IL-6 and others. Adiponectin 
is the principal hormone of adipose tissue with positive 
effects on metabolism. Its secretion stimulates weight loss. 
The main effect of adiponectin is directed through the 
activation or inhibition of the nuclear transcription factor 
kappaB (NF-kappaB) (28, 29). Along with adiponectin, 
fat cells in obesity release proinflammatory cytokines, 
such as TNF-? which activates NF-kappaB. Our result of 
a positive correlation between LDL and sRANKL is in 
line with these facts and further indicates the possibility 
of LDL to stimulate secretion of proinflammatory cyto-
kines from fat cells, which could affect bone metabolism 
in terms of increased bone resorption. The finding of a 
lower share of contribution of LDL in patients with anti-
resorptive therapy indicates lower serum sRANKL in 
their blood, which may be associated with reduced bone 
loss. This fact indirectly indicates the good choice of 
therapy for osteoporosis.
Statins and osteoporosis
Statins are applied in primary prevention in patients 
with hypercholesterolemia that persists despite adequate 
dietary regime conducted, and in secondary prevention 
in patients with myocardial infarction or ischemic stroke. 
Administration of statins is recommended in diabetic 
patients with total cholesterol above 5 mmol/l. Statins 
lower serum LDL cholesterol by 30 to 50% by inhibiting 
3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) 
reductase in the liver and thus indirectly cause an increase 
in the number of LDL receptors in the liver cells, which 
leads to an increased removal of LDL cholesterol from the 
blood (23-26). Besides anti-atherosclerotic effects, statins 
have additional effects on the bone, i.e. formation of os-
teoclasts is suppressed and activity of osteoblasts is in-
creased. According to recent knowledge, statins may be 
useful in acute inflammatory syndrome leading to reduc-
tion of morbidity and mortality in sepsis syndrome (23-
26).
The precise mechanisms by which statins act on the 
increased bone formation are explained by scientists who 
have studied the mechanisms of the action of bisphospho-
nates on bone metabolism. A focal point in the events 
provoked by these mechanisms is the synthesis of choles-
terol. In the first step of this synthesis, statins inhibit the 
enzyme HMG-CoA reductase which converts HMG-
CoA to mevalonate. In the second step, mevalonate is 
converted to geranyl pyrophosphate which is converted 
to farnesyl pyrophosphate by action of farnesyl pyrophos-
phate synthase. Bisphosphonates inhibit farnesyl pyro-
phosphate synthase (23-26, 30, 31). Osteoclasts use cer-
tain lipid products formed in the synthesis of cholesterol, 
and formation of these lipid products is inhibited by 
bisphosphonates and statins. Therefore, both of these 
medications lead to apoptosis of osteoclasts, which is re-
flected in the dynamics of bone turnover. Patients receiv-
ing both anti-lipidemic and anti-resorptive therapy have 
positive balance between bone resorption and formation, 
with reduced incidence of osteoporotic fractures (23-26, 
30, 31). The strongest effect on inhibiting cholesterol 
pathway was observed for alendronate and risedronate 
and lipophilic statins such as simvastatin and lovastatin 
(10, 26).
So far studies have determined positive correlation of 
statins with parameters of bone densitometry, but there 
are few investigations involving bone turnover markers. 
Results of some studies suggest that atorvastatin enhanc-
es the effect of bisphosphonates in osteoporosis, while 
other studies have identified a reduced level of serum al-
kaline phosphatase in patients taking risedronate and 
atorvastatin (26). Our results suggest that osteocalcin is 
positive predictor in patients treated with statins. Statin 
groups and osteocalcin are exactly proportional, with the 
share of contribution of 10% (Table 4). 
Based on our results and consideration of favorable 
influence of statins on sRANKL, it can be concluded that 
bone metabolism is improved in patients with prolonged 
duration of statin therapy. 
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